Advertisement

T wave positivity in lead aVR is associated with mortality in patients with cardiac resynchronization therapy

  • Yahya Kemal İçen
  • Yurdaer Dönmez
  • Hasan Koca
  • Mehmet Uğurlu
  • Mevlüt Koç
Article
  • 48 Downloads

Abstract

Purpose

Positive T wave polarity in lead aVR (TPaVR) is associated with a poor prognostic indicator in patients with heart failure reduce ejection fraction (HFrEF). Our aim was to investigate the relationship between positive TPaVR and mortality in patients with cardiac resynchronization therapy defibrillator (CRT-D).

Methods

We included retrospectively 224 HFrEF patients with CRT-D in sinus rhythm. Laboratory, electrocardiographic (ECG), and echocardiographic data were recorded. T wave polarity was measured in lead DI, DII, and aVR from surface ECG.

Results

The patients were divided as living and deceased. They followed for 2.5 ± 0.9 years. Thirty-three patients (14.7%) died. Six patients (18.2%) were TPaVR positive before CRT-D and this number increased to 22 (66.6%) after CRT-D in the deceased group. Pulse (p = 0.049), hyperlipidemia (p = 0.022), and NT-proBNP levels were higher in the deceased group (p = 0.001). TPaVR before CRT-D (p < 0.001) and TPaVR after CRT-D (p < 0.001) were significantly positive in the deceased group. Positive TPaVR after CRT-D was the only independent predictor for mortality in binominal logistic regression analysis (OR 1.211, 95% CI 1.105–1.328, p < 0.001).

Conclusions

In CRT-D patients, a positive TPaVR in surface ECG may be a strong mortality indicator.

Keywords

Cardiac resynchronization Mortality ECG Lead aVR 

Notes

Compliance with ethical standards

The Local Ethics Committee of Cukurova University Medical Faculty approved our retrospective study.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202.CrossRefPubMedGoogle Scholar
  2. 2.
    Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J. 2004;25(18):1614–9.  https://doi.org/10.1016/j.ehj.2004.06.038.CrossRefPubMedGoogle Scholar
  3. 3.
    Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–46.  https://doi.org/10.1136/hrt.2003.025270.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.  https://doi.org/10.1002/ejhf.592. CrossRefPubMedGoogle Scholar
  5. 5.
    Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15(8):1070–118.  https://doi.org/10.1093/europace/eut206.CrossRefPubMedGoogle Scholar
  6. 6.
    Boriani G, Kranig W, Donal E, Calo L, Casella M, Delarche N, et al. A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. Am Heart J. 2010;159(6):1052–1058.e1.  https://doi.org/10.1016/j.ahj.2010.03.008.CrossRefPubMedGoogle Scholar
  7. 7.
    Bogale N, Witte K, Priori S, Cleland J, Auricchio A, Gadler F, et al. The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. Eur J Heart Fail. 2011;13(9):974–83.  https://doi.org/10.1093/eurjhf/hfr085.CrossRefPubMedGoogle Scholar
  8. 8.
    Goldberger JJ, Subačius H, Patel T, Cunnane R, Kadish AH. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2014;63(18):1879–89.  https://doi.org/10.1016/j.jacc.2013.12.021.CrossRefPubMedGoogle Scholar
  9. 9.
    Kireyev D, Arkhipov MV, Zador ST, Paris JA, Boden WE. Clinical utility of aVR-the neglected electrocardiographic lead. Ann Noninvasive Electrocardiol. 2010;15(2):175–80.  https://doi.org/10.1111/j.1542-474X.2010.00359.x.CrossRefPubMedGoogle Scholar
  10. 10.
    Ducas R, Ariyarajah V, Philipp R, Ducas J, Elliott J, Jassal D, et al. The presence of ST-elevation in lead aVR predicts significant left main coronary artery stenosis in cardiogenic shock resulting from myocardial infarction: the Manitoba cardiogenic shock registry. Int J Cardiol. 2013;166(2):465–8.  https://doi.org/10.1016/j.ijcard.2011.11.003.CrossRefPubMedGoogle Scholar
  11. 11.
    Kobayashi A, Misumida N, Aoi S, Kanei Y. Positive T wave in lead aVR as an independent predictor for 1-year major adverse cardiac events in patients with first anterior wall ST-segment elevation myocardial infarction. Ann Noninvasive Electrocardiol. 2017;22(6)  https://doi.org/10.1111/anec.12442.
  12. 12.
    Misumida N, Kobayashi A, Fox JT, Hanon S, Schweitzer P, Kanei Y. Predictive value of ST-segment elevation in lead aVR for left main and/or three-vessel disease in non-ST-segment elevation myocardial infarction. Ann Noninvasive Electrocardiol. 2016;21(1):91–7.  https://doi.org/10.1111/anec.12272.CrossRefPubMedGoogle Scholar
  13. 13.
    Tanaka Y, Konno T, Tamura Y, Tsuda T, Furusho H, Takamura M, et al. Impact of T wave amplitude in lead aVR on predicting cardiac events in ischemic and nonischemic cardiomyopathy patients with an implantable cardioverter defibrillator. Ann Noninvasive Electrocardiol. 2017;22(6)  https://doi.org/10.1111/anec.12452.
  14. 14.
    Strauss DG, Selvester RH, Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. Am J Cardiol. 2011;107(6):927–34.  https://doi.org/10.1016/j.amjcard.2010.11.010.CrossRefPubMedGoogle Scholar
  15. 15.
    Warner RA, Hill NE, Mookherjee S, Smulyan H. Diagnostic significance for coronary artery disease of abnormal Q waves in the “lateral” electrocardiographic leads. Am J Cardiol. 1986;58(6):431–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Tan SY, Engel G, Myers J, Sandri M, Froelicher VF. The prognostic value of T wave amplitude in lead aVR in males. Ann Noninvasive Electrocardiol. 2008;13(2):113–9.  https://doi.org/10.1111/j.1542-474X.2008.00210.x.CrossRefPubMedGoogle Scholar
  17. 17.
    Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007;50(12):1150–7.  https://doi.org/10.1016/j.jacc.2007.04.095.CrossRefPubMedGoogle Scholar
  18. 18.
    Al-Zaiti SS, Fallavollita JA, Canty JM, Carey MG. The prognostic value of discordant T waves in lead aVR: a simple risk marker of sudden cardiac arrest in ischemic cardiomyopathy. J Electrocardiol. 2015;48(5):887–92.  https://doi.org/10.1016/j.jelectrocard.2015.06.013.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Al-Zaiti SS, Fallavollita JA, Wu YB, Tomita MR, Carey MG. Electrocardiogram-based predictors of clinical outcomes: a meta-analysis of the prognostic value of ventricular repolarization. Heart Lung. 2014;43(6):516–26.  https://doi.org/10.1016/j.hrtlng.2014.05.004.CrossRefPubMedGoogle Scholar
  20. 20.
    Phan D, Narayanan K, Uy-Evanado A, Teodorescu C, Reinier K, Chugh H, et al. T-wave reversal in the augmented unipolar right arm electrocardiographic lead is associated with increased risk of sudden death. J Interv Card Electrophysiol. 2016;45(2):141–7.  https://doi.org/10.1007/s10840-015-0078-1.CrossRefPubMedGoogle Scholar
  21. 21.
    Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. N Engl J Med. 2005;352(15):1539–49.  https://doi.org/10.1056/NEJMoa050496.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Yahya Kemal İçen
    • 1
  • Yurdaer Dönmez
    • 1
  • Hasan Koca
    • 1
  • Mehmet Uğurlu
    • 1
  • Mevlüt Koç
    • 1
  1. 1.Health Sciences University, Cardiology DepartmentAdana City HospitalAdanaTurkey

Personalised recommendations